GNPX

Genprex (GNPX)

Genprex Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:GNPX

1 2 3 4 5 6 7 8 9 10 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/05/14	21:31	PR Newswire (US)	Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa® Immunogene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer	NASDAQ:GNPX	Genprex Inc
2024/05/13	21:31	PR Newswire (US)	Genprex Announces the Appointment of Jose A. Moreno Toscano as Chairman of the Board of Directors	NASDAQ:GNPX	Genprex Inc
2024/05/09	21:11	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:GNPX	Genprex Inc
2024/05/09	07:08	PR Newswire (US)	Genprex Announces the Passing of its Co-Founder and Chief Executive Officer, Rodney Varner	NASDAQ:GNPX	Genprex Inc
2024/05/01	21:31	PR Newswire (US)	Genprex to Present and Participate at Upcoming May Investor and Industry Conferences	NASDAQ:GNPX	Genprex Inc
2024/04/09	21:31	PR Newswire (US)	Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting	NASDAQ:GNPX	Genprex Inc
2024/04/03	21:31	PR Newswire (US)	Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa® Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer	NASDAQ:GNPX	Genprex Inc
2024/04/02	21:31	PR Newswire (US)	Genprex Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex® Delivery System	NASDAQ:GNPX	Genprex Inc
2024/03/23	05:10	PR Newswire (US)	Genprex Announces Closing of $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules	NASDAQ:GNPX	Genprex Inc
2024/03/20	02:24	PR Newswire (US)	Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules	NASDAQ:GNPX	Genprex Inc
2024/03/19	21:36	PR Newswire (US)	Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules	NASDAQ:GNPX	Genprex Inc
2024/03/12	22:01	PR Newswire (US)	Genprex Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa® Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat Cancers	NASDAQ:GNPX	Genprex Inc
2024/03/06	23:18	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:GNPX	Genprex Inc
2024/03/06	22:30	PR Newswire (US)	Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting	NASDAQ:GNPX	Genprex Inc
2024/02/26	22:45	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:GNPX	Genprex Inc
2024/02/22	06:34	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:GNPX	Genprex Inc
2024/02/22	06:32	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:GNPX	Genprex Inc
2024/02/22	06:28	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:GNPX	Genprex Inc
2024/02/15	04:14	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:GNPX	Genprex Inc
2024/02/07	22:15	PR Newswire (US)	Genprex Expands Nonclinical Programs into New Therapeutic Indications with Research Collaborators	NASDAQ:GNPX	Genprex Inc
2024/02/06	21:30	PR Newswire (US)	Genprex to Present at Upcoming BIO CEO & Investor Conference	NASDAQ:GNPX	Genprex Inc
2024/02/05	22:15	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:GNPX	Genprex Inc
2024/02/05	21:30	PR Newswire (US)	Genprex Announces First Patient Dosed in Phase 2a Expansion of Acclaim-1 Clinical Study of Reqorsa® Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer	NASDAQ:GNPX	Genprex Inc
2024/02/02	21:30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:GNPX	Genprex Inc
2024/01/31	23:00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:GNPX	Genprex Inc
2024/01/31	22:42	PR Newswire (US)	Genprex Announces 1-for-40 Reverse Stock Split Effective February 2, 2024	NASDAQ:GNPX	Genprex Inc
2024/01/06	06:17	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:GNPX	Genprex Inc
2024/01/05	21:00	PR Newswire (US)	Genprex Provides Business Update and Outlook for 2024	NASDAQ:GNPX	Genprex Inc
2023/12/19	06:35	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:GNPX	Genprex Inc
2023/12/14	06:50	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:GNPX	Genprex Inc